Mallinckrodt (MNK) Mentioned Cautiously at Citron Research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mallinckrodt (MNK) Short Report Appears to Overstate Acthar CMS Sales - Leerink
November 16, 2016 1:57 PM ESTLeerink Partners analyst Jason Gerberry said Citron Research's latest short report on Mallinckrodt plc (NYSE: MNK) appears to overstate Acthar CMS sales.
Gerberry commented, "MNK shares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report (LINK) appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net.,... More
